Evidence map›Paper›PMID 40649365›Full record

ArticleMolecules (Basel, Switzerland)2025

Dual Opioid-Neuropeptide FF Small Molecule Ligands Demonstrate Analgesia with Reduced Tolerance Liabilities.

Marco Mottinelli, V Blair Journigan, Samuel Obeng, Victoria L C Pallares, Christophe Mѐsangeau, Coco N Kapanda, Stephen J Cutler, Janet A Lambert, Shainnel O Eans, Michelle L Ganno and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marco MottinelliDepartment of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.ORCID 0000-0001-5725-0439
V Blair JourniganDepartment of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Samuel ObengDepartment of Cellular and Systems Pharmacology, College of Pharmacy, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.ORCID 0000-0002-9644-0750
Victoria L C PallaresDepartment of Cellular and Systems Pharmacology, College of Pharmacy, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.
Christophe MѐsangeauDepartment of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Coco N KapandaDepartment of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Stephen J CutlerDepartment of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Janet A LambertDepartment of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Shainnel O EansDepartment of Cellular and Systems Pharmacology, College of Pharmacy, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.
Michelle L GannoTorrey Pines Institute for Molecular Studies, Port St. Lucie, FL 34987, USA.
Wanhui ShengDepartment of Cellular and Systems Pharmacology, College of Pharmacy, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.
Tamara KingDepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Abhisheak SharmaDepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA.ORCID 0000-0003-0553-4039
Catherine MollereauCentre de Recherches sur la Cognition Animale (CRCA-CBI), Université de Toulouse, 169, Avenue Marianne Grunberg-Manago, 31062 Toulouse, France.
Bonnie A AveryDepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Jay P McLaughlinDepartment of Cellular and Systems Pharmacology, College of Pharmacy, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.ORCID 0000-0001-9851-9342
Christopher R McCurdyDepartment of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.ORCID 0000-0001-8695-2915

Funding

Center of Research Excellence in Natural Products Neuroscience (CORE-NPN)P20GM104932 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2012 to 2016
$10.0M
NIH HHS 1R01DA034777-20NIH HHS P20 GM104932NIH National Center for Advancing Translational Sciences UL1TR001327
6 · The paper itself

Abstract

Neuropeptide FF (NPFF) receptor antagonists prevent morphine-mediated antinociceptive tolerance, and compounds with dual mu opioid receptor (MOR) agonist and NPFF antagonist activity produce antinociception without tolerance. Compounds synthesized showed affinities in radioligand competition binding assays in the nM and µM range at the opioid and NPFF receptors, respectively, and displayed substitution-dependent functional profiles in the [

Indexed as

AnalgesicsAnalgesics, OpioidReceptors, NeuropeptideAnalgesiaAnimalsDrug ToleranceHumansHyperalgesiaLigandsMaleMiceMorphineOligopeptidesRatsReceptors, Opioid, muAnalgesicsAnalgesics, OpioidLigandsMorphineneuropeptide FF receptorOligopeptidesphenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamideReceptors, NeuropeptideReceptors, Opioid, mudesigned multiple ligandsneuropeptide FFnociceptionopioidtolerance

Identifiers

PMID40649365
PMCPMC12251305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.